IGC Pharma
7 hedge funds and large institutions have $166K invested in IGC Pharma in 2017 Q4 according to their latest regulatory filings, with 4 funds opening new positions, 0 increasing their positions, 1 reducing their positions, and 3 closing their positions.
113% more capital invested
Capital invested by funds: $78K → $166K (+$88K)
33% more first-time investments, than exits
New positions opened: 4 | Existing positions closed: 3
17% more funds holding
Funds holding: 6 → 7 (+1)
100% less repeat investments, than reductions
Existing positions increased: 0 | Existing positions reduced: 1
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SB
Suntrust Banks
Atlanta,
Georgia
|
+$30.4K |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$11.2K |
| 3 |
TDC
Thompson Davis & Co
Richmond,
Virginia
|
+$5.53K |
| 4 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
+$923 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PAM
Panagora Asset Management
Boston,
Massachusetts
|
-$27K |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$12K |
| 3 |
UBS Group
Zurich,
Switzerland
|
-$11K |
| 4 |
VF
Virtu Financial
New York
|
-$3K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
1
Creative Planning
Overland Park,
Kansas
| $65K | – | – | – |
|
|
SB
2
Suntrust Banks
Atlanta,
Georgia
| $55K | +$30.4K | +55,000 | New |
|
|
3
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
| $20K | +$11.2K | +20,221 | New |
|
|
VF
4
Virtu Financial
New York
| $12K | -$3K | -5,427 | -31% |
|
|
TDC
5
Thompson Davis & Co
Richmond,
Virginia
| $10K | +$5.53K | +10,000 | New |
|
|
LTFS
6
Ladenburg Thalmann Financial Services
Miami,
Florida
| $2K | – | – | – |
|
|
7
Royal Bank of Canada
Toronto,
Ontario, Canada
| $2K | +$923 | +1,670 | New |
|
|
PAM
8
Panagora Asset Management
Boston,
Massachusetts
| – | -$27K | -76,561 | Closed |
|
|
9
Citadel Advisors
Miami,
Florida
| – | -$12K | -32,404 | Closed |
|
|
10
UBS Group
Zurich,
Switzerland
| – | -$11K | -29,838 | Closed |
|
IGC Hedge Fund Activity: Q4 2017 in Review
7 of the 4,409 institutional investors tracked by Wall St. Rank reported a position in IGC Pharma (IGC) for Q4 2017, worth a combined $166K — up 113% from $78K a quarter earlier.
Buyers outnumbered sellers: 4 funds opened new IGC positions and 3 closed out — a net gain of 1 holder — while 0 added to existing stakes and 1 trimmed.
The largest buyer was Suntrust Banks, opening a new position worth an estimated $30.4K. The largest seller was Panagora Asset Management, exiting entirely with an estimated $27K sold.
- 7 institutional investors held IGC Pharma (IGC) as of Q4 2017, up from 6 in Q3 2017.
- Funds reported $166K of IGC Pharma stock for Q4 2017, up 113% quarter-over-quarter.
- 4 funds opened new IGC Pharma positions in Q4 2017 and 3 closed out, a net change of +1 holder.
- The largest IGC Pharma buyer in Q4 2017 was Suntrust Banks, an estimated $30.4K added.
- The largest IGC Pharma seller in Q4 2017 was Panagora Asset Management, an estimated $27K sold.
Based on aggregated 13F filings for Q4 2017.